This case described in the literature, concerns a Caucasian patient of unspecified gender, who was participating in 
a phase II study to investigate the activity and tolerability of pemetrexed (Alimta) in combination with 
the growth factor receptor (EGFR)-targeting monoclonal anti000y matuzumab compared with 
xed alone as second-line therapy for patients with advanced non-small cell lung cancer (NSCLC). Median 
age of patient was 63 years (range 46-78 years). Patient's medical history was not reported. Concomitant 
medications included matuzumab for NSCLC, dexamethasone taken the day before, the day of and the day after 
infusion, cy lamin one '   of 1000 g during the week preceding the first dose of pemetrexed and 
every nine weeks thereafter and folic acid 350-1'000ug with at least 5 daily doses taken during the seven day period 
pr .0 the first dose of pemetrexed and o uing daily throughout treatment, up to 21 days after the last dose 
of axed. The patient received pemetrexed 500 mg/m2 intravenous (IV) infusion over 10 minutes day 1 every 
3 weeks in combination with matuzumab 1.00 g IV infusion over 1 hour, once every 3 weeks, for the treatment of 
advanced non-small cell lung cancer, beginning on an unspecified date. Sometimes after starting pemetrexed and 
Print Time: 02-SEP-2014 01:09 PM If a field is blank, there is no data for that field Page 699 of 631 
FDA - Adverse Event Reporting System (FAERS) 
FOIA Case Report Information 
rnattinalab, the patient experienced pneumonia and respiratory failure. It was re!. that the patient died due to 
PheurnOnlaengfrespiristory failure. The patient died within 30 days of the last administration of pemetrexed 
treatment. Respiratoty failure and pnuemonia were considered serious for other reasons by the company. 
Complete 0 0,0  c0o  unts including platelets and absolute neutrophil count were assessed weekly while the patient 
wasiapernetrexed. Information on corrective treatment was unknown. Action taken with pemetrexed in 
combkiititiOn with.matuzurnab was unknown. Outcome of the event was fatal (death). It was unknown if any autopsy 
was done. The . 8 0 0 authors stated that the event of pneumonia and,respi.3   0,  f ailure were possibly related to 
the use of suspect drug, pemetrexed. This case was cross-referenced to the following cases US201011001002 
and 1118201011001910. This case was described in the article: Socinski.M, Schiller.J, von Pawel.J, Schutt.P, 
Ansarl.R, Thomas.M et.al. Pemetrexed with or without. Matuzumab as Second-Line Treatment for Patients with 
AMID, Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 2010 Dec; 5(12): 1-9.